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Conversion of prion protein (PrPC) into a pathological isoform (PrPSc) during prion infection occurs in lipid rafts and is
dependent on cholesterol. Here, we show that prion infection
increases the abundance of cholesterol transporter, ATP-binding cassette transporter type A1 (ATP-binding cassette transporter type A1), but reduces cholesterol efflux from neuronal
cells leading to the accumulation of cellular cholesterol.
Increased abundance of ABCA1 in prion disease was confirmed
in prion-infected mice. Mechanistically, conversion of PrPC to
the pathological isoform led to PrPSc accumulation in rafts, displacement of ABCA1 from rafts and the cell surface, and
enhanced internalization of ABCA1. These effects were abolished with reversal of prion infection or by loading cells with
cholesterol. Stimulation of ABCA1 expression with liver X
receptor agonist or overexpression of heterologous ABCA1
reduced the conversion of prion protein into the pathological
form upon infection. These findings demonstrate a reciprocal
connection between prion infection and cellular cholesterol
metabolism, which plays an important role in the pathogenesis
of prion infection in neuronal cells.
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Cholesterol has increasingly been recognized to play an
important role in the pathogenesis of many neurodegenerative
diseases. Dysregulation of cholesterol metabolism in the brain
has been implicated in the pathogenesis of Niemann Pick type
C disease (1), Alzheimer disease, and prion disease (2). Prion
diseases, or transmissible spongiform encephalopathies, are
fatal neurodegenerative disorders affecting humans and animals. A key event in the pathogenesis of prion disease is the
conversion of the host-encoded cellular prion protein (PrPC)7
to a pathological misfolded isoform (PrPSc). PrPC is enriched
with an ␣-helical structure, is monomeric, and is susceptible to
protease digestion, whereas PrPSc mainly consists of a ␤-sheet
structure that can form insoluble protease-resistant deposits in
the brain (3). The exact cellular conversion site and molecular
mechanism(s) involved in the conversion of PrPC to PrPSc are
still unknown; however, it has been suggested that conversion
takes place in lipid rafts (4, 5). There are several lines of evidence
that support this as follows: (i) depletion of cellular cholesterol
from the plasma membrane diminishes PrPSc formation (5, 6); (ii)
PrPSc and PrPC are both glycosylphosphatidylinositol-anchored
proteins residing in the lipid rafts (5, 7); (iii) in vitro, membraneassociated PrPC is resistant to conversion unless phosphatidylinositol-specific phospholipase C is added to the reaction promoting insertion of the infectious PrPSc into the rafts to initiate
conversion (4); (iv) the modification of properties of lipid raft
domains significantly inhibits PrPSc propagation (8).
Lipid rafts are highly dynamic, short lived microdomains
found in the plasma membrane and enriched with cholesterol
and sphingolipids. Lipid rafts have also been implicated as a
platform for a number of key cellular pathways, such as protein
sorting, membrane trafficking, signal transduction, and activation of the immune response (9, 10). The abundance and integ7

The abbreviations used are: PrPC, cellular prion protein; ABCA1, ATP-binding
cassette transporter type A1; ABCG1, ATP-binding cassette transporter
type G1; apoA-I, apolipoprotein A-I; apoE, apolipoprotein E; LXR, liver X
receptor; POPC, 1-palmitoyl-2-oleylphosphatidylcholine; PE, phosphatidylethanolamine; PPS, sodium pentosan polysulfate; PrP, prion protein;
SR-BI, scavenger receptor class B, type I.
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Background: Cholesterol plays an important role in the pathogenesis of neurodegenerative diseases.
Results: Prion infection increased abundance of cholesterol transporter ABCA1 but reduced its functionality. Stimulation of
ABCA1 reduced the conversion of prion into the pathological form.
Conclusion: ABCA1 plays a key role in pathogenesis of prion disease.
Significance: There is a reciprocal connection between prion infection and cholesterol metabolism.

Prions Regulate Cholesterol Metabolism in Brain

EXPERIMENTAL PROCEDURES
Cells—Three murine cell models were used as follows: the
murine hypothalamic cell line GT1-7 (18), the murine neuroblastoma cell line N2a, and murine fibroblasts 3T3. Neuronal
cells were infected with the mouse adapted human prion strain
M1000, and the efficiency of infection was monitored every five
passages; both cell lines were strongly infected during the
course of experimentation (data not shown). The M1000 prion
strain was prepared from brains of terminally sick BALB/c mice
infected with the mouse-adapted human Fukuoka-1 prion
strain (19). All experiments were performed within the first 15
passages following infection with prions. Cells were infected as
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described previously (20). For sodium pentosan polysulfate
(PPS) treatment, mock- and prion-infected GT1-7 cells were
treated with PPS (50 g/ml) or vehicle continuously for 8 days.
The cells were passaged every 3 days, and treatment was
repeated. 3T3 mouse fibroblast cells were infected using rabbit
kidney 13 (RK13) epithelial cell lysates, which have been
infected with M1000 prion strain, as described previously (21).
3T3 cells were transfected with mouse ABCA1-specific siRNA
(siRNAABCA1) or scrambled siRNA (siRNAC) (Ambion). Transfection was performed using Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s protocol.
Overexpression of human ABCA1 in 3T3 cells was achieved
by transfecting the cells with human ABCA1-GFP plasmid,
using Lipofectamine LTX plus reagent (Invitrogen) according to the manufacturer’s protocol.
Cell Blot Assay—Cells were plated and grown to confluence
on plastic coverslips (Nunc) and transferred on to a nitrocellulose membrane, followed by proteinase K digestion and immunostaining using anti PrP antibody (ICSM-18) as described previously (22).
Animals—For the time course analysis, BALB/c mice (6 – 8
weeks of age) were inoculated in the left parietal region under
methoxyflurane inhalational anesthesia with a 1% (w/v) homogenate of M1000 infected brain tissue as described previously
(23). Mice were anesthetized (methoxyflurane) and euthanized
at predetermined time points (3, 6, 10, 13, and 17 weeks postinoculation) or when they exhibited clear signs of terminal
prion disease. Histology (hematoxylin/eosin staining) and
immunohistochemistry using polyclonal anti-ABCA1 antibody
(Abcam) were performed on formalin-fixed tissues. Homogenates were prepared in PBS containing complete protease
inhibitor mix and normalized for equivalent protein. Brain
lysates were prepared as described previously (20). Immunohistochemistry was performed at the Animal Facility and Histology Core Services at the Melbourne Brain Centre (Melbourne,
Victoria, Australia).
Acceptors—High density lipoprotein (HDL) (1.083 ⬍ d
⬍1.21 g/liter) was isolated from frozen human plasma by
sequential centrifugation in KBr solutions. ApoE discs (reconstituted HDL based on apoE) were prepared with recombinant
apoE protein, cholesterol, and 1-palmitoyl-2-oleylphosphatidylcholine (POPC), using the cholate dialysis method as
described (24). The POPC/cholesterol/apolipoprotein molar
ratio of the apoE discs was 114:13:1. Concentration of the
acceptors was expressed as protein concentration. Methyl
␤-cyclodextrin䡠cholesterol complexes were prepared as
described previously (25) and used at the final concentration
5 mM.
Cholesterol Efflux Assay—Cholesterol efflux was performed
as described previously (26). Concentrations of the acceptors
were as follows: apoA-I, 30 g/ml; HDL, 40 g/ml, and apoE
discs, 15 g/ml. Duration of the efflux incubation was 4 h, and
LXR agonist TO-901317 was used at final concentration of
4  M.
Real Time Quantitative PCR—Cells were seeded in a 6-well
tissue culture plates and treated or untreated with 4 M
TO-901317 for 18 h. Total RNA was isolated using the TRIzol
method. cDNA were synthesized from 2 g of RNA with random
VOLUME 289 • NUMBER 2 • JANUARY 10, 2014
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rity of these microdomains are highly dependent on the availability of cholesterol (10).
Cholesterol is required for PrPC cell surface expression and
stabilization (11), and cholesterol depletion inhibits the replication of the pathological isoform in prion-infected cells by
disrupting the trafficking of PrPC to lipid rafts (6). Cholesterol
biosynthesis has been shown to be enhanced in prion infection,
which was associated with increased levels of cellular cholesterol (12), suggesting a link between cholesterol metabolism
and prion propagation. Treatment of prion-infected mice with
inhibitors of cholesterol biosynthesis prolonged the latent stage
of infection, reduced neuronal loss, and significantly delayed
death (13). Collectively, these findings demonstrate that not
only prion replication is dependent on the availability of cholesterol, but prions may be capable of manipulating cholesterol
metabolism to meet their requirement for cholesterol. Paradoxically, it was reported that prion infection also increases the
abundance of ATP-binding cassette transporter A1 (ABCA1)
(14). Outside the brain, the main function of ABCA1 is to facilitate cholesterol removal from cells to the lipid-poor acceptor,
apolipoprotein A-I (apoA-I). Increased abundance of ABCA1 is
generally associated with enhanced reverse cholesterol transport and a reduction of cellular cholesterol content (15). Cholesterol homeostasis in the CNS is separated from the rest of the
body as the blood brain barrier does not permit lipoprotein
permeability. Within the brain, ABCA1, along with another
transporter, ATP-binding cassette transporter G1 (ABCG1),
transfers cholesterol and phospholipids to the lipid acceptor,
apolipoprotein E (apoE)-containing lipoproteins. ApoE is produced by astrocytes (16, 17) and contributes to regulation of
cholesterol homeostasis in neuronal cells.
Given the importance of cholesterol in the pathogenesis of
prion disease and the key role of ABCA1 in maintaining cholesterol homeostasis, we investigated the impact of prion infection
on the regulation, trafficking, and function of ABCA1. We
found that prion infection post-transcriptionally inhibits the
ABCA1-dependent cholesterol efflux pathway by redistributing ABCA1 away from the plasma membrane and lipid raft
microdomains, ultimately leading to increased amounts of free
cholesterol within prion-infected cells. Conversely, overexpression of ABCA1 in prion-infected cells significantly reduced the
abundance of PrPSc, demonstrating a key involvement of this
pathway in prion propagation. These findings reveal a novel
element of pathogenesis of prion disease that could potentially
be targeted by therapeutic approaches.

Prions Regulate Cholesterol Metabolism in Brain
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20 times. Lysates were pelleted by centrifugation, and supernatant was collected. The remaining cell pellet was lysed by passing through the 27-gauge needle 20 times on ice, and large
debris pelleted by centrifugation and supernatant was collected
and combined with the first collection. The collected supernatant was combined with 50% OptiPrep density gradient
medium to produce a final concentration of 25% and loaded at
the bottom of the 8.9-ml ultracentrifuge tube. A 20 to 5% continuous gradient was laid on top of the lysates. Samples were
centrifuged for 18 h, 52 ⫻ 103 ⫻ g at 4 °C. After centrifugation,
0.6-ml fractions were collected, and proteins were precipitated
using the methanol/chloroform method. Fractions were analyzed by Western blotting.
Lipidomics Analysis—GT1-7 cells were collected, resuspended in 0.5 M NaCl, 20 mM Tris, pH 7.0, and cell pellets were
sonicated. Lipids were extracted using chloroform/methanol
(2:1) from cell lysates (20 g of cellular protein). Lipid analysis
was performed by liquid chromatography, electrospray ionization-tandem mass spectrometry (LC ESI-MS/MS) using a Agilent 1200 liquid chromatography system, and Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turbo-ion
spray source (350 °C) and Analyst 1.5 and MultiQuant data systems using a Zorbax C18, 1.8 m, 50 ⫻ 2.1-mm column (Agilent Technologies). Lipid concentrations were calculated by
relating the peak area of each species to the peak area of the
corresponding internal standard.
Other Methods—For PrPSc detection, cells were collected
and lysed, and 100 g of protein was digested with proteinase K
at a final concentration of 25 g/ml for 60 min at 37 °C. Digestion was stopped by adding 5 mM phenylmethylsulfonyl fluoride to the lysates for 5 min on ice. Brain homogenates were
prepared as described previously (19, 20); for Western blots,
brain homogenates were diluted in lysis buffer. The following
antibodies were used for Western blot analysis: monoclonal
anti-ABCA1 antibody (Abcam); polyclonal anti-ABCG1 antibody
(Abcam); polyclonal anti-LDL receptor antibody (Abcam);
in-house monoclonal anti-PrP antibody L3; and horseradish peroxidase-conjugated anti-IgG (GE Healthcare).
Statistics—The data are presented mean ⫾ S.D. of quadruplicate determinations. Statistical significance of the differences was assessed by Student’s t test.
Ethics Statement—Animal experimentation was approved by
the Animal Ethics Committee of Melbourne University and
conformed to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health).

RESULTS
Prion Infection Increases Abundance of ABCA1 but Reduces
Cholesterol Efflux—To investigate the effect of prion infection
on cellular cholesterol metabolism, we assessed changes in the
abundance of the LDL receptor and the two key cholesterol
transporters ABCA1 and ABCG1. The third key cholesterol
transporter, SR-BI, is not expressed in neuronal cells (28). Prion
infection significantly increased the abundance of ABCA1 protein in GT1-7 cells (Fig. 1, A and B). This was evident in both
unstimulated cells and in cells where expression of ABCA1 was
stimulated with LXR agonist TO-901317. In contrast, prion
JOURNAL OF BIOLOGICAL CHEMISTRY
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primers using High Capacity cDNA reverse transcription kit
(Invitrogen) according to the manufacturer’s recommendation.
Specific primers for each gene (Abca1 (Mm00442626_m1),
Abcg1 (Mm00437390_m1), Ldl-r (Mm00440169_m1), and
Prnp (Mm00448389_m1)) were from Invitrogen. The PCRs
were done in triplicate and normalized to gapdh mRNA. The
relative amount of mRNA was calculated by using the comparative threshold cycle (⌬⌬CT) method.
Confocal Microscopy—Cells were seeded in 8-well chamber
slides (Thermo Scientific or Ibidi) and maintained at 37 °C for
24 h. The cells were washed with PBS, fixed with 4% paraformaldehyde for 15 min at room temperature, washed with PBS,
and permeabilized with 0.1% Triton X-100 for 10 min. After
blocking with 10% goat serum in PBS for 1 h, primary antibodies (monoclonal anti-ABCA1 antibody and polyclonal antiLAMP1 antibody) in PBS containing 1% goat serum were added
to the cells for 18 h at 4 °C. Cells were then washed with PBS,
incubated with appropriate fluorescent-conjugated secondary
antibodies (Invitrogen), and counter-stained with 4⬘,6⬘-diamidino-2-phenylindole (DAPI; Sigma; 1 g/ml) for 2 h at
room temperature. Confocal microscopy performed using a
Leica TCS SP2 imaging system.
Cell Surface ABCA1 Assay—Cells were grown in a 75-cm2
flask and activated with LXR agonist TO-901317 (4 M) for
18 h. Cells were washed with cold PBS and incubated for 30 min
at 4 °C in PBS with Sulfo-NHS-SS-Biotin (Pierce) (final concentration 0.5 mg/ml). Cells were then washed twice with cold
quench buffer (50 mM Tris, 0.1 mM EDTA, 150 mM NaCl) and
once with cold PBS. Cells were scraped into PBS containing
complete protease inhibitor mixture (Roche Applied Science)
and lysed with 5 mM Tris, pH 7.5. Large debris removed by low
speed centrifugation and cellular membrane fraction was isolated by centrifugation at 100,000 ⫻ g for 1 h at 4 °C. Pellet was
resuspended in a 50 mM Tris, 22 mM mercaptoethanol, 1% Triton X-100 buffer containing complete protease inhibitor mixture. Membrane lysates were mixed with UltraLink Plus immobilized streptavidin beads (Pierce) and incubated for 2 h at 4 °C.
After extensive washing with PBS, the beads were incubated
with SDS-PAGE sample buffer containing 50 mM DTT and
heated at 50 °C for 30 min. Beads were then pelleted by centrifugation. Samples of supernatant were analyzed using Western
blot. To trace ABCA1 internalization, biotinylated cells were
returned to 37 °C and incubated for 30 min. Biotin from biotinylated proteins remaining at the cell surface was cleaved off by
incubating cells with 50 mM tris(2-carboxyethyl)phosphine
(Sigma) in Tris-based buffer for 30 min at 4 °C. The remaining
biotinylated ABCA1 was considered the internalized portion.
The cells were lysed with RIPA buffer (Pierce), and protein was
mixed with UltraLink Plus immobilized streptavidin beads
(Pierce), incubated for 2 h at 4 °C, and processed as described
for cell surface ABCA1 assay.
Lipid Raft Isolation—Lipid rafts were isolated using a detergent-free method (27). Briefly, cells were grown in a 75-cm2
flask and activated with LXR agonist TO-901317 (4 M) for 18 h
prior to collection. Cells were washed with PBS and resuspended in a 20 mM Tris-HCl, pH 7.8, 250 mM sucrose, 1 mM
CaCl2, and 1 mM MgCl2 buffer containing protease inhibitor
mixture. Cells were lysed by passing through a 27-gauge needle
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TABLE 1
The effect of the LXR agonist and prion infection on cholesterol efflux from GT1-7 cells
Efflux from
mock-infected cells

Efflux from
prion-infected cells

LXR agonist

Acceptor

(⫺) TO901317

ApoA-I
ApoE/POPC
HDL

0.13 ⫾ 0.01
0.89 ⫾ 0.02
2.44 ⫾ 0.28

0.04 ⫾ 0.02
0.59 ⫾ 0.09
1.90 ⫾ 0.11

⬍0.001
⬍0.02
⬍0.01

(⫹) TO901317

ApoA-I
ApoE/POPC
HDL

0.45 ⫾ 0.03
1.17 ⫾ 0.11
3.99 ⫾ 0.27

0.08 ⫾ 0.05
0.80 ⫾ 0.05
2.04 ⫾ 0.05

⬍0.0001
⬍0.001
⬍0.0001

%

%

TABLE 2
Nonspecific cholesterol efflux from GT1-7 cells
Cholesterol efflux
Cells
Mock GT1-7
Infected GT1-7
p

ⴚTO901317
0.536 ⫾ 0.181
0.460 ⫾ 0.107
⬎0.5

ⴙ TO901317
%

0.516 ⫾ 0.235
0.460 ⫾ 0.188
⬎0.5

efflux (i.e. the efflux in the absence of acceptors) was not affected
by prion infection (Table 2).
The findings with GT1-7 cells were confirmed using a second
model, mouse neuroblastoma N2a cells. In contrast to GT1-7
cells, LXR agonist did not affect cholesterol efflux from N2a
cells to any of the acceptors (Fig. 1H). Consistent with the findings on GT1-7 cells, prion infection resulted in a significant
reduction in cholesterol efflux to apoA-I, apoE/POPC, and
HDL (Fig. 1H). Thus, cholesterol efflux from prion-infected
cells was inhibited despite the elevated abundance of ABCA1
and unchanged abundance of ABCG1.
Prion Infection Increases Abundance of ABCA1 in Vivo—To
investigate if prion infection affects abundance of the ABCA1
transporter in vivo, we compared ABCA1 abundance in brain
tissue homogenates from clinically affected prion-infected
mice and age-matched noninfected controls. As shown in Fig.
2A, with quantitation shown in Fig. 2B, ABCA1 abundance was
significantly elevated in prion-infected brain samples; the infection in these brain samples was confirmed using Western blotting as shown in the lower panel of Fig. 2A.
Fig. 2C shows abundance of ABCA1 in brain homogenates of
mice infected with prions for various periods of time; quantitation of the abundance is shown in Fig. 2D. Increased abundance
of ABCA1 was only evident at the terminal stage of the infection
(Fig. 2, C and D).
Fig. 3 shows histology and immunochemical staining of
ABCA1 in sections of the thalamus and hippocampus of mockand prion-infected mice. It reveals general ABCA1 immunoreactivity in the cell bodies and neuropil of both mock- and prioninfected mice, with a more prominent expression observed in
the bodies of cells located in the thalamus. There was no significant change in ABCA1 abundance at 10 weeks post-inocula-

FIGURE 1. Prion infection increases ABCA1 protein abundance via a post-transcriptional mechanism but impairs cholesterol efflux. A, mouse GT1-7
cells infected (Inf) with prion or mock-infected (Mock) were treated or not with LXR agonist 4 M TO901317 for 24 h. ABCA1, ABCG1, LDL receptor, and GAPDH
proteins were analyzed with Western blotting. B, densitometric quantification of ABCA1 protein abundance relative to GAPDH in mock- and prion-infected
GT1-7 cells. *, p ⬍ 0.05; **, p ⬍ 0.01. C–E, effects of prion infection on mRNA expression levels of Abca1 (C), Abcg1 (D), and Ldlr (E) were assessed by RT-PCR. F,
cholesterol efflux to apoA-I (30 g/ml), apoE discs (15 g/ml), and HDL (40 g/ml) from mock- or prion-infected GT1-7 cells, without LXR agonist treatment. G,
same as F, but cells were treated with LXR agonist. H, cholesterol efflux to lipid acceptors apoA-I (30 g/ml), apoE discs (15 g/ml), and HDL (40 g/ml) were
measured in mock- and prion-infected N2a cells. Cells were treated (⫹) or untreated (⫺) with TO901317 (TO). *, p ⬍ 0.05; **, p ⬍ 0.01, and ***, p ⬍ 0.001; ns,
nonsignificant.
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infection and LXR agonist had no effects on the protein levels of
ABCG1 and the LDL receptor (Fig. 1A).
To investigate the mechanism of stimulation of ABCA1
abundance, the expression levels of Abca1, Abcg1, and Ldlr
genes were measured by quantitative real time PCR and normalized to the expression of Gapdh. Abundance of Abca1
mRNA increased by 10-fold following treatment with LXR agonist in both mock- and prion-infected cells (Fig. 1C). Prion
infection had no significant effect on Abca1 expression in both
LXR agonist-treated and untreated cells. Treatment with LXR
agonist caused a modest (50%) increase in the level of Abcg1
mRNA and had no effect on the level of Ldlr mRNA (Fig. 1, D
and E). Prion infection did not influence the expression of
Abcg1 and Ldlr with or without treatment with LXR agonist.
Collectively, these findings suggest that prion infection specifically enhances the abundance of the ABCA1 transporter via a
post-transcriptional mechanism.
The functionality of ABCA1 is reflected in the rate of cholesterol efflux to lipid-free acceptors, mainly apolipoprotein A-I
(apoA-I). However, the levels of apoA-I in the CNS are reported
to be very low, and the most abundant apolipoprotein found in
the CNS is apoE (29). Therefore, we tested the effects of prion
infection on ABCA1 functionality by measuring cholesterol
efflux to recombinant discoidal lipoproteins composed of apoE
and POPC, apoA-I, or HDL. As expected, when cholesterol
efflux from nonactivated mock-infected GT1-7 cells was measured, more cholesterol was released to the lipidated acceptors,
apoE/POPC and HDL, than to the lipid-free apoA-I (Fig. 1F).
Unexpectedly, significantly less cholesterol was released from
prion-infected cells compared with mock-infected cells to all three
acceptors (Fig. 1F). When cells were activated with LXR agonist,
the percentage of efflux to lipid-free apoA-I, apoE/POPC, and
HDL was increased by 200, 30, and 64%, respectively (Table 1).
Prion infection resulted in a significant reduction of cholesterol
efflux from cells activated with LXR agonist to all three acceptors
(Fig. 1G). When ABC-dependent efflux (defined as a difference
between the efflux from activated versus nonactivated cells) was
calculated, ABC transporter-specific cholesterol efflux to apoA-I
and HDL was reduced by 80% and to apoE/POPC by 45% in prioninfected cells compared with mock-infected cells. Nonspecific

p
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FIGURE 2. Prion infection (Inf) increases ABCA1 protein abundance in vivo. A, top panel, ABCA1 abundance in brains of mock and M1000-infected BALB/c
mice. Bottom panel, detection of PrPC and PrPSc from brain homogenates treated (⫹) or not treated (⫺) with PK. B, densitometric quantitation of Western blots
presented in A; **, p ⬍ 0.001. Inf, infected. C, Western blot analysis of ABCA1 abundance in the brain of prion-infected mice at different stages of infection (weeks
after inoculation). D, densitometric quantitation of Western blots presented in C; *, p ⬍ 0.001.

tion, when vacuolation was first observed in the hippocampus
and thalamus of prion-infected mice (30). However, a change in
ABCA1 localization was observed in the CA3 and fimbria
regions of the hippocampus 17 weeks post-inoculation, when
the region exhibited clear vacuolation and spongiform change.
A change in ABCA1 localization was also observed in cells of
the thalamus; this, however, varied with the degree of vacuolation observed.
Prion Infection Impairs Cholesterol Efflux by Affecting ABCA1
Localization—Reduced cholesterol efflux on a background of elevated abundance of ABCA1 indicated that prion infection had
affected ABCA1 functionality. A common reason for impaired
ABCA1 functionality is mislocalization of ABCA1 away from the

794 JOURNAL OF BIOLOGICAL CHEMISTRY

cell surface, resulting in a significant reduction of cholesterol
efflux (31). To test this possibility, we evaluated the subcellular
localization of ABCA1. Although prion infection increased the
total amount of ABCA1 in the cells, the amount of ABCA1
associated with cellular membranes (both plasma membrane
and intracellular membranes) was similar in mock- and prioninfected cells (Fig. 4, A and B). Moreover, the abundance of cell
surface ABCA1 in prion-infected cells was reduced by 50%
compared with mock-infected cells (Fig. 4, A and C) thus
explaining the discrepancy between the ABCA1 level and the
level of cholesterol efflux. More specifically, we demonstrated a
significant increase of co-localization between ABCA1- and
LAMP1-positive endosomes (Fig. 4D) in prion-infected cells. It
VOLUME 289 • NUMBER 2 • JANUARY 10, 2014
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appears that prion infection causes a redistribution of ABCA1
away from the cell surface into intracellular compartments.
To test this hypothesis, we measured the rate of ABCA1
internalization; the findings are shown in Fig. 4, E and F. In
these experiments cell surface ABCA1 was first labeled with
biotin; the reaction was stopped, and biotinylated ABCA1 was
allowed to internalize. The biotin label was then removed from
proteins remaining at the cell surface, leaving only the internalized proteins labeled with biotin. Although the amount of cell
surface ABCA1 was reduced by prion infection (Fig. 4A), the
amount of internalized ABCA1 was elevated (Fig. 4E, quantitation from several experiments is shown in Fig. 4F) indicating a
higher rate of internalization.
Lipid rafts play an important role in both prion infection and
ABCA1 functionality. On the one hand, lipid rafts are thought
to be the conversion site where physiological PrPC misfolds into
PrPSc. On the other hand, lipid rafts are the main source of
cholesterol for ABCA1-dependent cholesterol efflux (32), and
lipid rafts and ABCA1 exist in a dynamic equilibrium (33–35).
We therefore investigated co-localization of PrP and ABCA1 in
membrane fractions separated by Optiprep density gradient
centrifugation; Flotillin-1 was used as a raft marker and
Na⫹K⫹-ATPase as a non-raft marker. PrP was detected in both
raft and non-raft fractions; consistent with previous reports
(36), prion infection caused a considerable re-distribution of
JANUARY 10, 2014 • VOLUME 289 • NUMBER 2
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FIGURE 3. Changes in ABCA1 expression correlates with degree of pathology associated with prion infection in vivo. Histology (H&E) and immunohistochemistry (ABCA1) were performed on sagittal brain sections of mockand prion-infected mice prepared at the indicated time points (weeks
post-inoculation) or when they exhibited signs of clinical prion disease (terminal). Images of thalamus and the CA3/fimbria of the hippocampus are
shown (n ⱖ2 mice per time point).

PrP from non-raft to raft fractions (Fig. 4, G and H). Distribution of ABCA1 in relation to rafts is likely to be cell-specific (37);
in GT1-7 cells, we found that ABCA1 was localized in rafts in
both mock- and prion-infected cells. In mock-infected cells,
most ABCA1 was found in fractions 4 –5, whereas in the
infected cells, most ABCA1 was detected in lighter fractions
3– 4 (Fig. 4G). Quantitative assessment shows that ABCA1
abundance in lipid rafts decreased in prion-infected cells (Fig.
4I). Thus, in GT1-7 cells, conversion of PrPC into PrPSc led to
the redistribution of PrP into rafts and of ABCA1 away from
rafts. The decrease of ABCA1 in rafts occurred without elevation of ABCA1 abundance in non-raft fractions of the plasma
membrane, supporting the hypothesis that prion infection
causes internalization of ABCA1.
Reversal of the Effects of Prion Infection on ABCA1 and Cholesterol Efflux—To directly connect changes in cholesterol efflux and
ABCA1 abundance with prion infection, we performed “rescue”
experiments. GT1-7 cells were treated with PPS, a compound that
cures prion infection in vitro by disrupting the interactions
between PrP and endogenous glycosaminoglycans at the cell surface, thereby reducing PrPSc accumulation (38). After treatment with PPS for 8 days at a noncytotoxic concentration,
there was a significant reduction of PrPSc present in prioninfected cells (Fig. 5A). Furthermore, ABCA1 abundance in
PPS-treated prion-infected cells was reduced to a level similar to mock-infected cells where there was no effect of PPS
on ABCA1 abundance (Fig. 5, B and C). PPS also reversed the
effect of prion infection on cholesterol efflux to apoE/POPC
and HDL, and there was no effect of PPS on cholesterol efflux
from mock-infected cells (Fig. 5D). Thus, increased ABCA1
abundance and impairment of cholesterol efflux were
reversed when prion infection was cured.
Given that cellular cholesterol level affects both prion infection and abundance and functionality of ABCA1, we investigated
how changes in cellular cholesterol would modulate the effects of
prion infection on cholesterol efflux. Loading the cells with exogenous cholesterol using methyl-␤-cyclodextrin䡠cholesterol complex resulted in an increase in ABCA1 abundance in both mock
and infected cells eliminating the difference between prion-infected and mock-infected cells (Fig. 5E). Addition of exogenous
cholesterol also increased cholesterol efflux to all acceptors in
both infected and mock-infected cells eliminating the difference between the two (Fig. 5F). Thus, the effects of prion infection on ABCA1 abundance and cholesterol efflux are dependent on cell cholesterol content.
Effect of Prion Infection on Cellular Lipids—To investigate
the physiological consequences of impairment of cholesterol
efflux by prion infection, we performed lipidomic analysis on
mock- and prion-infected GT1-7 cells. Fig. 5G presents data
with different subclasses of lipids combined and categorized
into seven main classes; full lipidomic analysis is presented in
supplemental Table S1. In prion-infected cells, cholesterol
esters, free cholesterol, phosphatidylethanolamine (PE),
and triglycerides were significantly increased, although no
changes were detected in other lipid classes when compared
with mock-infected cells (Fig. 5G). When the abundance of different lipids was normalized to total PC level, again, in prioninfected cells cholesterol ester, free cholesterol, PE, and triglyc-
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FIGURE 4. Prion infection (Inf) impairs cholesterol efflux by redistributing ABCA1 from the cell surface and lipid rafts. A, abundance of ABCA1 from whole lysate,
cellular membrane fraction, and biotinylated ABCA1 at the cell surface in mock and prion-infected GT1-7 cells. B, densitometric quantification of total and membraneassociated ABCA1 protein in A. C, densitometric quantification of cell surface ABCA1 protein in A. D, intracellular localization of ABCA1 in mock (top row) and
prion-infected GT1-7 cells (bottom row). Scale bar, 20 m. E, ABCA1 internalization. Whole lysate and internalized ABCA1 were assessed using Western blotting. For
internalized ABCA1, cell surface protein in mock- and prion-infected GT1-7 cells were labeled with sulfo-SS-biotin, followed by incubation at 37 °C for 30 min. Surface
biotin was cleaved to detect the amount of ABCA1 internalized. Biotinylated protein was bound to streptavidin resin, and ABCA1 abundance was analyzed by Western
blotting. F, densitometric quantification of whole lysate and internalized ABCA1 protein abundance in mock- and prion-infected GT1-7 cells. Mean ⫾ S.D., n ⫽ 3, *,
p ⬍ 0.05. G, distribution of ABCA1 and PrP in lipid rafts versus non-raft fractions of plasma membrane. *, p ⬍ 0.05. H, ratio of PrP abundance in lipid rafts versus non-raft
fractions. I, ABCA1 abundance in lipid rafts of GT1-7 cells. *, p ⬍ 0.05.
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DISCUSSION
It is established that an imbalance of neuronal cholesterol
homeostasis plays a key role in pathogenesis of many neurodegenerative diseases, including prion disease. However, the
mechanismsbywhichprioninfectionaffectscholesterolhomeostasis in neuronal cells remains unclear. The main finding of
this study is that prion infection impairs cholesterol efflux from
neuronal cells despite elevated levels of ABCA1 and unchanged
levels of ABCG1. Mechanistically, the effects on cholesterol
efflux were explained by displacement of ABCA1 from lipid
rafts and the cell surface to intracellular compartments. These

effects were reversed when prion infection was cured or when
the cells were loaded with cholesterol. Physiologically, prion
infection led to the accumulation of free and esterified cholesterol, PE, and triglycerides in neuronal cells. Furthermore,
overexpression of ABCA1 reduced the severity of prion infection. The identification of PE accumulation is significant given
the recent findings that this lipid alone can act as a sole cofactor
in forming infectious prion molecules from highly purified
recombinant sources of PrP (39, 40).
It has been thought that prion infection requires high levels
of cellular cholesterol because of its reliance on lipid rafts. PrPC
is partly located within lipid rafts, and this is where conversion
to PrPSc is thought to take place. It is also known that these
microdomains are very sensitive to cell cholesterol content. It
was speculated that localization of PrPC in rafts is necessary for
conversion because it allows for a high local concentration of
PrPC and for a “detergent-like” environment, both factors
favoring polymerization and conversion of prion proteins (41).
ABCA1 not only functions to reduce cellular cholesterol content, but its overexpression can also specifically reduce the
number of rafts, whereas increased abundance of rafts reduces
the abundance of ABCA1 at the plasma membrane (33, 34, 42).
Based on these considerations, we propose the following mechanistic model of how and why prion infection affects cholesterol efflux (Fig. 8). In uninfected neuronal cells, both ABCA1
and PrPC proteins are localized in rafts. Monomeric PrPC does
not interfere with the capacity of ABCA1 to remove cellular
cholesterol to the main cholesterol acceptor in the cerebrospinal fluid, apoE-based HDL. The formation of PrPSc in the rafts
as a result of prion infection may change the structure of lipid
rafts, transforming them into larger, more rigid structures. This
can lead to the displacement of ABCA1 from rafts and the cell
surface to the intracellular compartments, presumably late
endosomes, ultimately reducing ABCA1 functionality and
resisting removal of cholesterol from rafts. Reduction of cholesterol efflux leads to accumulation of cholesterol in the cells,
which partitions into rafts stabilizing the platform for the accumulation and further conversion of PrPC to PrPSc. Thus, conversion of the prion protein and reduction of cholesterol efflux
may form a vicious cycle contributing to the progression of the
prion disease. Regulation of the delivery arm of cholesterol
homeostasis is affected by prions (12), limiting the compensatory response of the host cells to attempts to stimulate cholesterol efflux by up-regulating the key element of the removal arm
of cholesterol homeostasis, ABCA1. Post-translational mechanisms are apparently responsible for the elevation of the
ABCA1 levels in neuronal cells at prion infection, likely reflecting an accumulation of cholesterol in these cells. Elevation of
ABCA1 was not observed in prion-infected fibroblasts, possibly

FIGURE 5. Reversal of the effects of prion infection (Inf). A, cells were treated with PPS (50 g/ml) or vehicle continuously for 8 days. Western blots of cell
lysate with and without PK treatment are shown after development with anti-PrP antibody. B, ABCA1 protein abundance was assessed by Western blotting
comparing pre- and post-PPS treatment. C, densitometric quantification of ABCA1 protein abundance before and after treatment with PPS in mock- and
prion-infected GT1-7 cells. **, p ⬍ 0.01. D, cholesterol efflux to apoE discs (15 g/ml) and HDL (40 g/ml) were measured in mock and infected GT1-7 cells,
treated and untreated with PPS. **, p ⬍ 0.01; ***, p ⬍ 0.001. E, ABCA1 protein abundance after prion-infected and mock GT1-7 cells were loaded with cholesterol
by incubating with 5 mM cholesterol-loaded methyl-cyclodextrin (M␤CD-Chol). F, cholesterol efflux in mock- and prion-infected GT1-7 cells, incubated with or
without cholesterol loaded methyl-cyclodextrin. *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001. G and H, lipidomic analysis for mock- and prion-infected GT1-7 cells;
absolute values (G) or normalized to PC content (H). CE, cholesterol esters; FC, free cholesterol; Cer, ceramides; PC, phosphatidylcholine; PI, phosphatidylinositol;
PS, phosphatidylserine; SM, sphingomyelin; TG, triglycerides.**, p ⬍ 0.01; ***, p ⬍ 0.001.
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erides were significantly increased, whereas other lipids
remained unchanged (Fig. 5H).
Elevation of ABCA1 Reduces PrPSc Formation—The effects of
prion infection on cholesterol metabolism indicate the possibility that resisting these changes may affect prion infection.
We tested whether levels of prion protein are affected by
activation of LXR, a potent activator of ABCA1 expression
and cholesterol efflux. When prion-infected cells were
treated with the LXR agonist TO-901317, there were no
observable changes in the level of prion gene (Prnp) mRNA
(Fig. 6A) or in the level of PrPC protein (Fig. 6, B and C).
However, the total amount of PrPSc in infected cells was
significantly reduced upon LXR agonist treatment (Fig. 6, B
and D). The reduction of PrPSc affected heavier, presumably
glycosylated, isoforms of PrPSc (Fig. 6E).
Activation of LXR affects many genes; therefore, we corroborated findings of the experiments with LXR agonist by overexpressing and silencing ABCA1 by heterologous transfection.
Because of the difficulty in transfecting GT1-7 cells with efficiency sufficient for testing cholesterol efflux, 3T3 mouse fibroblasts were infected with mouse prion and transfected either
with ABCA1 or siRNAABCA1. Infection of 3T3 cells with prions resulted in reduction of cholesterol efflux to apoA-I,
apoE discs, and HDL similar to the effects seen in prioninfected neuronal cells (Fig. 7A). In contrast to neuronal
cells, we did not observe an elevation of cellular ABCA1
levels as a result of prion infection (Fig. 7, B and C). Overexpression of heterologous ABCA1 increased the abundance of
ABCA1 in both infected and mock-infected cells (Fig. 7, B
and C). Overexpression of ABCA1 did not affect levels of
PrPC, but a statistically significant reduction in the level of
PrPSc was observed (Fig. 7D and quantitation in E and F),
similar to the effects of an LXR agonist.
Transfection of cells with siRNAABCA1 resulted in an almost
complete elimination of ABCA1 from both mock-infected and
prion-infected cells (Fig. 7, G and H). Silencing of ABCA1 did
not affect the levels of PrPC or PrPSc (Fig. 7I and quantitation in
J and K).
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FIGURE 6. LXR agonist TO901317 reduced PrPSc formation in GT1-7 cells. A, effects of LXR agonist TO901317 on mRNA expression levels of Prnp as assessed
by RT-PCR in mock- and prion-infected GT1-7 cells either treated (⫹) or untreated (⫺) with TO901317. B, PrPC and PrPSc protein abundance was assessed by
Western blot in TO901317 (TO)-treated (⫹) and -untreated (⫺) cells. C–E, densitometric quantification of PrPC (C) and PrPSc (D and E) protein abundance in cells
treated (⫹) or untreated (⫺) with TO901317. Total PrPSc abundance is shown in D, and the abundance of the individual glycosylated PrP isoforms is shown in
E; ratios of specific PrP band to GAPDH are shown; for PK-treated samples GAPDH values in parallel samples untreated with PK were used. *, p ⬍ 0.05. ns,
nonsignificant.

because these cells usually do not accumulate excessive cholesterol. Regulation of ABCA1 functionality by its mislocalization
is a well established phenomenon exploited by pathogens, such
as HIV (42). In prion disease, when rafts are “occupied” with
PrPSc, ABCA1 is dysfunctional. However, loading cells with free
cholesterol overcomes this prion-inflicted restriction, likely by
providing sufficient cholesterol and a cholesterol-rich environment required for ABCA1 to be stable and functional (37), thus
JANUARY 10, 2014 • VOLUME 289 • NUMBER 2

elevating cholesterol efflux to the level seen in uninfected cells.
Interestingly, prion disease specifically targets ABCA1, but
affects cholesterol efflux not only to the lipid-free apoA-I,
which is the preferred substrate of ABCA1, but also to HDL and
lipidated apoE, which are preferred substrates for two other
transporters, ABCG1 and SR-BI. However, this seems to be a
peculiarity of the neuronal cells as it was demonstrated before
(28) and confirmed in this study that SR-BI is not expressed in
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FIGURE 7. Effect of ABCA1 overexpression and silencing on PrPSc formation in 3T3 cells. A, cholesterol efflux to apoA-I (30 g/ml), apoE discs (15 g/ml),
and HDL (40 g/ml) from mock- or prion-infected 3T3 cells; cells were activated with 4 M LXR agonist (mean ⫾ S. D., n ⫽ 3). Inf, infected. **, p ⬍ 0.01 versus
mock-infected cells. B, Western blot analysis of ABCA1 abundance in 3T3 cells after transient transfection with mock (control) and human ABCA1 plasmid
(⫹ABCA1). C, relative change of ABCA1 abundance in mock- and prion-infected 3T3 cells after transfection with mock and ABCA1 plasmid. ABCA1 abundance
was expressed as fold change compared with mock (control) (mean ⫾ S.D., n ⫽ 3). *, p ⬍ 0.05; ***, p ⬍ 0.001. D, Western blot analysis of PrPC and PrPSc in 3T3
cells transiently transfected with mock and human ABCA1 plasmids. E and F, densitometric quantification of PrPC (F) and PrPSc (G) in 3T3 cells transfected with
mock and ABCA1 plasmids. (mean ⫾ S.D., n ⫽ 3). ***, p ⬍ 0.001 versus mock-infected 3T3 cells. G, Western blot analysis of ABCA1 abundance in 3T3 cells after
transfection with scrambled (siRNAScr) and mouse ABCA1-specific siRNA (siRNAABCA1, final concentration 20 nM). H, relative protein fold change of
ABCA1 in mock-infected and prion-infected 3T3 cells after transfection with siRNAABCA1 or siRNAScr. ABCA1 abundance was expressed as fold change
compared with mock-infected cells (mean ⫾ S.D., n ⫽ 3). ***, p ⬍ 0.001. I, Western blot analysis of PrPC and PrPSc in mock- and prion-infected 3T3 cells
transfected with siRNAScr (⫺) and siRNAABCA1 (⫹). Densitometric quantification of PrPC (J) and PrPSc (K) in mock- and prion-infected 3T3 cells transfected
with siRNAScr and siRNAABCA1.
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